Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04330664 · ClinicalTrials.gov registry record · Phase 1
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT04330664 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 86 participants.
The verdict
NCT04330664, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Interventions
- DRUG MRTX849
- DRUG TNO155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04330664
The ClinicalTrials.gov registry entry for NCT04330664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRTX849 is the first listed.
NCT04330664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04330664 about?
NCT04330664 is a clinical study titled "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)". This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
What is the current status of trial NCT04330664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2020-04-07. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT04330664?
The interventions under investigation include: MRTX849 (DRUG), TNO155 (DRUG).
Who is sponsoring clinical trial NCT04330664?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.